<PAGE>
- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-KSB
(MARK ONE)
/X/ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the fiscal year ended March 31, 1999
OR
/ / TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from to
Commission file number 0-25377
NURESCELL INC.
(NAME OF SMALL BUSINESS ISSUER IN ITS CHARTER)
NEVADA 33-0805583
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
1400 BRISTOL STREET N., SUITE 240, NEWPORT BEACH, CALIFORNIA 92660
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
ISSUER'S TELEPHONE NUMBER: (949) 752-0071
SECURITIES REGISTERED UNDER SECTION 12(b) OF THE EXCHANGE ACT:
TITLE OF EACH CLASS NAME OF EACH EXCHANGE ON WHICH REGISTERED
None None
SECURITIES REGISTERED UNDER SECTION 12(g) OF THE EXCHANGE ACT:
Common Stock, $.0001 par value
(TITLE OF CLASS)
Class "A" Common Stock Purchase Warrants
(TITLE OF CLASS)
Class "B" Common Stock Purchase Warrants
(TITLE OF CLASS)
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or
for such shorter period that the issuer was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days.
Yes / / No /X/
Check if there is no disclosure of delinquent filers in response to
Item 405 of Regulation S-B contained in this form, and no disclosure will be
contained, to the best of issuer's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. /X/
Issuer's net loss for its most recent fiscal year (ended March 31,
1999) was $(644,526).
The aggregate market value of the voting and non-voting common equity
held by nonaffiliates of the issuer, based upon the average bid and asked price
of such common equity on June 23, 1999, as reported by the OTC Bulletin Board,
was approximately $13,439,000. Shares of Common Stock held by each officer and
director and by each person who owns 5% or more of the outstanding Common Stock
have been excluded in that such persons may be deemed to be affiliates. This
determination of affiliate status is not necessarily a conclusive determination
for other purposes.
<PAGE>
The number of outstanding shares of the issuer's Common Stock on June
23, 1999 was 13,096,000.
DOCUMENTS INCORPORATED BY REFERENCE None
- 2 -
<PAGE>
Transitional Small Business Disclosure Format (CHECK ONE): Yes /x/ No / /
- 3 -
<PAGE>
PART I
NOTE: NURESCELL INC. HAS ELECTED TO FOLLOW DISCLOSURE ALTERNATIVE 2 IN THE
PREPARATION OF THIS REPORT.
ITEM 6. DESCRIPTION OF BUSINESS.
THIS REPORT CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933 AND SECTION 21E OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. AS A RESULT OF CERTAIN FACTORS
DESCRIBED BELOW AND ELSEWHERE IN THIS REPORT, AND OTHER FACTORS, ACTUAL RESULTS
COULD DIFFER MATERIALLY FROM THOSE PROJECTED IN THOSE FORWARD- LOOKING
STATEMENTS.
GENERAL. Nurescell Inc. (the "Company" or "Registrant") was formed in
Nevada on May 12, 1998 for the purpose of developing and commercially exploiting
a proprietary radiation shielding technology (the "Nurescell Technology") for
use by the nuclear power industry and others producing, handling or storing
radioactive materials. The Nurescell Technology is being designed for
incorporation into the structural components of new and existing nuclear reactor
facilities in order to provide a cost-effective safeguard from the lethal effect
of radiation while achieving a minimal disruption to existing physical
facilities. It is also being designed as a containment material which will
provide an attractive alternative to the conventional concrete/steel entombment
and glassification technologies currently used to store ever-increasing amounts
of spent nuclear fuel and other radioactive waste. In addition, it is expected
to provide an innovative shielding material critical to advanced accelerator and
defense research applications. The Nurescell Technology is based upon a
proprietary formulation which was acquired from Adrian A. Joseph, Ph.D., the
Company's President and majority shareholder, in June 1998. See "Item 11.
Interest of Management and Others in Certain Transactions." The intended market
and primary application for the Company's products will be nuclear power plants,
accelerators and waste storage facilities worldwide. Based on the potential
applications for the Nurescell Technology, as well as the potential markets, the
Company believes that there is a substantial opportunity to develop a profitable
business over the next two years. However, because the Company is in its
start-up and research and development and testing stage, it currently has no
final products and no sales, and is not currently marketing the Nurescell
Technology. As a result, there can be no assurance that the Company or the
Nurescell Technology will be successful or that the Company can or will achieve
any sales or profitability.
THE PROPOSED PRODUCTS. The Nurescell Technology is expected to be
superior to existing and competing technology which is based upon a ceramic
silicon foam (also originally developed by Dr. Joseph). It is believed that
products based on the Nurescell Technology will possess characteristics which
include:
- Favorable Heat Transfer and Diffusion Properties
- High Radioactive Resistance
- High Compressive and Tensile Strengths
- Corrosion and Shrinkage Resistance
- Fugitive Gassing Properties
- Resistance to Weathering and Aging
- Ease of Application and Handling
- A Non-Hazardous Application Process
In addition, the Company's products are expected to result in
significant reductions in the weight and volume of encapsulated nuclear waste
and/or on-site spent fuel depository space. If achieved, those characteristics
are believed by the Company to be superior to ceramic silicon foam (which does
not have mechanical strength, shrinks when subjected to high temperatures and is
comprised of hydrogen chains which are a potential danger in high temperature
environments) and thus correct some of the most acute problems associated with
conventional nuclear materials and the resultant radioactive waste problems. In
addition, the physical performance characteristics of Nurescell Technology
materials are expected to expedite advances in nuclear accelerator and
innovative fuel projects, which require special performance materials for their
facilities.
The Company's products are currently in the sample testing stage. At
this point, the Company has completed a "Statement of Work" with the U.S.
Department of Energy ("DOE") and Battelle Memorial Institute, Pacific Northwest
National Laboratory ("PNNL"), and is in the process of finalizing a Cooperative
Research and Development Agreement for product testing and market development
with the DOE and PNNL (the latter of which will conduct the sample testing).
After commencement, it is anticipated that PNNL's test and evaluation process
will take approximately two years.
- 4 -
<PAGE>
In parallel with the work by PNNL, the Company has entered into an
agreement with the University of Missouri for product testing with respect to
high levels of alpha, beta and gamma radiation. At this point, samples have been
shipped to the University of Missouri and the first set of test results is
expected around July 15, 1999.
After the performance of the Nurescell Technology has been
satisfactorily evaluated by PNNL, the Company will seek to incorporate Nurescell
Technology products into field studies of specialized applications and into
bench scale and field trials of specialized private enterprise equipment.
Simultaneous with that phase, the Company will use its best efforts to seek out
and form various strategic alliances for the use of its products in nuclear
material handling equipment and applications.
THE MARKET. The Company considers every nuclear power plant in the
world to be a potential customer for the Nurescell Technology which, because of
its mechanical properties (including structural strength), can be used in
materials for construction of new nuclear facilities or in the retrofitting of
existing facilities. At this time, there are approximately 108 nuclear power
plants in the United States, of which approximately 40 are not currently in
operation. Of the operating nuclear power plants, approximately 50 are owned by
the DOE and the balance are owned by public and private utilities. There are
also currently approximately 360 nuclear power plants in the world which are not
located in the United States or Russia. Because accidents do occur at nuclear
power plants for a variety of reasons, management of the Company believes that a
cost-effective safety shield system for new and existing facilities is in great
demand.
The Company also believes that its products can play an important role
in the recovery and reuse of materials from existing nuclear warheads. As
nuclear arsenals in the U.S. and former Soviet Union are dismantled, this
application will grow in importance.
In light of the huge and steadily growing deposits of worldwide nuclear
waste and related materials (447,000 metric tons according to 1995 estimates),
the properties of the Nurescell Technology are believed to have a worldwide
market as the means of correcting the existing problems with the handling and
storage of spent reactor fuel and various other radioactive materials, such as
uranium mill tailings and accelerator wastes.
Because of their special shielding needs, it is expected that nuclear
accelerator projects, as well as projects involving innovative fuels and defense
research applications, will find the Nurescell Technology to be an important
factor in implementing those projects.
GOVERNMENTAL REGULATION. In the United States, the nuclear power
industry is highly regulated under the jurisdiction of the DOE and the Nuclear
Regulatory Commission ("NRC"), with the NRC having primary responsibility for
enacting and enforcing regulations designed to ensure the safety of nuclear
power plants. That regulatory authority extends from construction to all phases
of operations. In particular, the NRC has the authority to require nuclear power
plants to utilize specific measures to ensure and enhance their safety.
In the rest of the world, regulatory oversight of nuclear power plants
is effected through a Nuclear Safety Committee which is comprised of
representatives from throughout the world.
COMPETITION. The number of competitors offering proprietary products
designed to accomplish the same or similar effects as the Nurescell
Technology include Lockheed Martin, which is in the process of testing the
ceramic silicon foam technology, and SAE (France), which utilizes a
concrete-iron technology, among others. Other companies may currently have or
may succeed in developing products superior to the Nurescell Technology, or
may more effectively market such other products, either of which could
substantially reduce the potential market for products using the Nurescell
Technology.
MARKETING STRATEGY. At this time, the Company plans to divide its major
market into the following divisions:
- Reactor Spent Nuclear Fuel
- Department of Defense Special Projects
- EM-40 Environmental Management and Site Restoration
Programs
- Specialized Advanced Accelerator Materials
- High Level Nuclear Wastes
The Company's marketing strategy is to develop its products in
accordance with the specifications and design which will be required by the NRC
and DOE and, in some situations, the Department of Defense ("DOD"). The Company
will then seek to present the Nurescell Technology to the NRC, DOE and, as
appropriate, the DOD, with emphasis on both the efficacy of the technology and
the cost savings which the technology will allow by reducing downtime for
maintenance. This
- 5 -
<PAGE>
presentation will be made with the intent of having the NRC mandate that the
Nurescell Technology be installed in all nuclear power plants in the United
States. The Company believes that becoming the standard in the United States
will then result in the Nurescell Technology being accepted as the standard
worldwide. The Company's marketing organization structure will be based upon the
following:
- The use of Company technical personnel with
substantial nuclear physics and engineering,
field technical sales and corporate product
management experience at the corporate
level, each with a specific area of
technical expertise.
- Field Technical Sales Representatives with
successful, in-depth experience in nuclear
physics and engineering and technical sales
work located in those geographical areas
which will best serve the rapid development
of the Company's business.
- Presentations at nuclear power trade shows
where independent environmental engineering
and consulting companies can be made
increasingly aware of the Nurescell
Technology and the unique applications that
can serve their clients' needs.
If the Company is able to move ahead as planned, it expects to begin
involvement in a variety of nuclear markets by the end of 1999, including
commercial domestic and international nuclear plants, submarine-based nuclear
reactors, DOD and DOE nuclear waste site restoration projects and nuclear
accelerator materials.
PRODUCT MANUFACTURING AND INSTALLATION. At this time, samples of
Nurescell Technology products that are required by PNNL and the University of
Missouri are being prepared by Thermach Engineering, an experienced formulation
laboratory. Once mass production begins, the Company anticipates that a major
United States chemical manufacturing company will be a contract manufacturer of
products incorporating the Nurescell Technology. The Company has also
established contacts in Israel with the Atomic Nuclear Commission for the
purpose of establishing a manufacturing capacity. For installation of its
products, the Company anticipates contracting with engineering firms to install
those products in nuclear power plants and other applications identified by the
Company for the encapsulation of nuclear materials. The Company does not
anticipate any difficulty in obtaining the ingredients needed to manufacture its
products.
INTELLECTUAL PROPERTY RIGHTS. At this time, a United States patent has
been applied for with respect to certain elements of the Nurescell Technology
(patent application No. 09/187,641). To date, no patents have been issued
pending the results of further research, testing and legal work. It is
anticipated that the ingredients of the Nurescell Technology will also be
manufactured under secrecy agreements. In addition, the Company will pursue
foreign patents and other U.S. and foreign protection of its intellectual
property to the extent appropriate under the circumstances.
PERSONNEL. The Company currently has five employees (all of whom are
full-time), three part-time consultants and a technical Board of Advisors
currently comprised of one member. It is anticipated that additional employees
will be hired as the needs of the Company require. It is also anticipated that
the Company will utilize third party contractors to handle various of the
Company's needs as they arise.
PLAN OF OPERATION. The Company is in the very early stages of its
development. Consequently, its operations consist principally of research,
development and testing of the basic Nurescell Technology. Although the Company
intends to actively pursue research grants to fund either all or a portion of
this research, development and testing, any such revenues are not anticipated
prior to the fiscal quarter ending December 31, 1999. Additionally, there are no
assurances that the Company will obtain any grants or that any grant funding
received will be sufficient to meet all the Company's funding requirements,
either within this estimated time frame or in the future. Revenues associated
with actual commercial applications of the Nurescell Technology are not
anticipated for two years. From inception to March 31, 1999, the Company has
obtained approximately $995,000 in financing through the sale of equity
securities through two private offerings (the "Offerings"), each of which has
been completed. Through March 31, 1999, the Company utilized approximately
$648,000 of the proceeds of the Offerings to (i) commence patent applications
for the Nurescell Technology, (ii) identify, negotiate and finalize suitable
research, development and testing contracts, (iii) identify, negotiate and
finalize preliminary marketing consulting contracts and (iv) provide working
capital for the ongoing administrative and financing acquisition costs of the
Company. The approximately $347,000 of remaining proceeds from the Offerings is
being used to begin initial formal testing of the Nurescell Technology, continue
the pursuit of patents and provide administrative working capital. The Company
anticipates that its remaining capital will enable it to operate until September
1999. The Company's financial statements for the period from May 12, 1998 (date
of inception) to March 31, 1999 have been prepared assuming the Company will
continue as a going-concern. As noted in the Company's financial statements, the
presence of significant losses, negative cash flows and limited working capital,
- 6 -
<PAGE>
together with the uncertainties associated with the ability of the Company to
obtain additional capital, raise substantial doubts as to the Company's ability
to continue as a going-concern. See "Part F/S - Index to Financial Statements."
The Company's ability to continue as a going-concern will be questionable until
such time as it is able to generate sufficient revenues (from research grants
and/or commercial operations) in excess of expenses to sustain its normal
business activities. Until that time, the Company will depend on its ability to
raise additional capital through either commercial loans or equity or debt
offerings. At this time, the Company expects that it will need approximately $3
million in additional funding over the next two years in order to complete the
necessary research, development and testing of its Nurescell Technology. The
Company currently anticipates financing of at least $2 million to be derived
from a "best efforts" private offering of equity securities which is currently
being discussed with several private investors. It is anticipated that such
offering will then be followed by a public offering of approximately $5,000,000.
There can, however, be no guarantee that either of such offerings will be
successfully completed or that any additional funding will be available on terms
favorable to the Company or its shareholders, if at all. If sufficient funds are
not available when needed, the Company may be required to curtail its
operations, which could have a material adverse effect on the Company's
business, operating results and financial condition.
ITEM 7. DESCRIPTION OF PROPERTY.
The Company's executive office is located in leased premises of
approximately 2,200 square feet. The lease commenced on June 1, 1999 and
continues until May 31, 2002, with monthly rent of $3,679 which began on June 1,
1999 (subject to annual base rent increases of 2.9% commencing June 1, 2000).
The Company expects that this space will be sufficient for its executive offices
for the foreseeable future.
ITEM 8. DIRECTORS, EXECUTIVE OFFICERS AND SIGNIFICANT EMPLOYEES.
Set forth below is information regarding the directors and executive
officers of the Company. The Company has no significant employees other than
those described below and there are currently no other persons under
consideration to become directors or executive officers of the Company.
<TABLE>
<CAPTION>
NAME AGE POSITION
---- --- --------
<S> <C> <C>
William A. Wilson 84 Chairman of the Board (a Director
position)
Adrian A. Joseph 46 President
Rita M. Lavelle 50 Director and Vice President - Marketing
John R. Longenecker 45 Director and Vice President - Operations
Sharon Nitka 37 Director, Chief Financial Officer and Secretary
</TABLE>
WILLIAM A. WILSON has been the Chairman of the Board of the Company
since its inception on May 12, 1998. Mr. Wilson has approximately fifty years
of business experience in both the financial and manufacturing fields and is
currently an advisor and consultant to various high technology and financial
companies. Mr. Wilson is the former Chairman of the Board of Web Wilson Oil
Tools, Inc. and San Vicente Investments Co., and a former member of the
Boards of Directors of Jorgensen Steel Company, Penzoil Company, Disease
Detection International, Western Energy Management, Inc., Incomnet, Inc.,
National Registry Corporation, Orbit Technologies, Inc. and several privately
held companies. He is also a director and corporate Secretary of Tresis
International, a newly-formed corporation in which Adrian A. Joseph is the
majority shareholder. Mr. Wilson was a delegate to several Republican
conventions, Chairman of the Presidential Personnel Selection Committee
(Reagan Administration), Presidential envoy to the Holy See (Vatican), first
Ambassador to the Holy See (Reagan Administration) and a trustee of President
Reagan's personal trust. Mr. Wilson holds Bachelor of Science and Master of
Science degrees in Mechanical and Metallurgical Engineering from Stanford
University. Mr. Wilson devotes approximately 20% of his business time to the
Company.
ADRIAN A. JOSEPH, PH.D. has been the President of the Company since its
inception. Dr. Joseph holds a Ph.D. degree in nuclear physics from the Israel
Institute of Technology, which he earned in 1974. For 12 years prior to the
commencement of pre-organization work on the Company (which began in February
1996), Dr. Joseph was the founder and chief scientist and Chairman of the Board
of Orbit Technologies Inc., a publicly traded company engaged in developing
materials to treat existing hazardous waste. Dr. Joseph resigned his position
with Orbit Technologies Inc. in February 1996, but remains a shareholder of that
company. Dr. Joseph has developed many diverse technologies and holds 118 issued
patents and has over 200 active
- 7 -
<PAGE>
patent applications on file. Dr. Joseph's work has included metafusion (a
process for the fusion of metals at room temperature), low-cost titanium
refining and extraction, ultrasound technology for the reduction of viscosity in
fluids, and technologies in the coatings, plastics and foam areas. In 1994, he
received an Honors Award from the Euro-Asian Association of Physicists for High
Achievement in Nuclear Physics. Dr. Joseph also received his Bachelor of Science
degree in Electronics Engineering from the Israel Institute of Technology. Dr.
Joseph devotes essentially all of his business time to the Company.
RITA M. LAVELLE has been a director and Vice-President of the Company
since its inception. Since 1986, Ms. Lavelle has been the President of NuTECH
Enterprises, Inc., an environmental engineering and remediation company. From
1982 through 1983, Ms. Lavelle was appointed by President Ronald Reagan as the
Administrator of Hazardous Waste with the U.S. Environmental Protection Agency,
where she controlled a $2.5 billion budget directing the nationwide enforcement
and compliance efforts for U.S. hazardous waste handling and cleanup commonly
known as the Superfund. Prior thereto, Ms. Lavelle held positions which included
Director of Communications with Cordova Chemical and Aerojet, Director of
Marketing with Intercontinental and Continental Chemicals, Department
Information Officer with the California Department of Consumer Affairs, and
Publications Assistance in Governor Ronald Reagan's Administration in
California. Ms. Lavelle holds an MBA in Finance and Strategic Planning and
Marketing from Pepperdine University and a BA degree in Biology and Mathematics.
Ms. Lavelle devotes approximately 50% of her business time to the Company.
JOHN R. LONGENECKER has been a director and Vice-President of the
Company since its inception. Mr. Longenecker is also the President of
Longenecker & Associates, a management consulting firm with the high technology
and energy related businesses. Prior to the formation of Longenecker &
Associates in 1989, Mr. Longenecker was Chairman of General Atomics
International Services Corporation, a company which operates and maintains
nuclear power stations. From 1983 to 1987, Mr. Longenecker served in the Reagan
administration as the chief executive officer of the U.S. uranium enrichment
business in the DOE, and prior thereto worked in the United States' nuclear
reactor development program as the Director of Breeder Demonstration Projects
for the DOE. Mr. Longenecker received both his Bachelor of Science and Master of
Science degrees from Pennsylvania State University and is a member of that
institution's Industrial Professional Advisory Council. Mr.
Longenecker devotes approximately 20% of his business time to the Company.
SHARON NITKA has been a director and the Chief Financial Officer and
Secretary of the Company since its inception and is the sister of Adrian A.
Joseph. During the last five years, Ms. Nitka has also worked as a consultant
for Nagila Foods, Inc. ("Nagila"), a company which, among other things, operates
restaurants and prepares pre-packaged food items. Ms. Nitka's primary focus for
Nagila has been the development of an effective marketing strategy, including
community public relations. Other services for Nagila have included an in-depth
analysis of the operations management, which included creating a new branch of
delivery services and transforming Nagila's manual process to computerized
systems. Ms. Nitka has also held a variety of administrative and management
positions with various other companies. From 1985 to 1990, Ms. Nitka served as
the financial administrator of Orbit Technologies Inc. and a programmer analyst
with Metafuse Limited, both of which are or were controlled by Adrian A. Joseph.
Ms. Nitka holds a Bachelor degree in computer science and business and devotes
approximately 60% of her business time to the Company.
Subject to prior resignation or removal, the Company's directors serve
in that capacity until the next annual meeting of shareholders or until their
successors are elected or appointed and duly qualified. Officers are appointed
by the Board of Directors and serve in that capacity until resignation or
removal. Except as noted above, there are no family relationships by blood,
marriage or adoption among any directors and/or executive officers of the
Company, and there are no arrangements or understandings between any director or
executive officer and any other person pursuant to which such director or
executive officer was selected for his or her office or position. Except as
noted above, within the past five years (i) no petition under the federal
Bankruptcy Act or any state insolvency law has been filed by or against any
executive officer or director of the Company, and no receiver, fiscal agent or
similar officer has been appointed by a court for the business or property of
any such persons, or any partnership in which any of such persons was a general
partner at or within the two years before the time of such filing, or any
corporation or business association of which any such person was an executive
officer at or within the past two years and (ii) no director or executive
officer of the Company has been convicted in a criminal proceeding (excluding
traffic violations and other minor offenses).
ITEM 9. REMUNERATION OF DIRECTORS AND OFFICERS.
COMPENSATION. The following table sets out the compensation paid on a
cash basis from inception to March 31, 1999 to (i) each of the Company's three
highest paid officers or directors and (ii) the Company's officers and directors
as a group:
- 8 -
<PAGE>
<TABLE>
<CAPTION>
NAME OR IDENTITY OF GROUP TITLE COMPENSATION(1)
- --------------------------------------------- ----- ---------------
<S> <C> <C>
Adrian A. Joseph President $136,783(2)
Sharon Nitka Chief Financial Officer, Secretary & Director $ 30,928(3)
William A. Wilson Director $ 26,333(4)
All officers and directors as a group (5 persons) $229,225(5)
</TABLE>
- -----------------
(1) Does not include group life, health, hospitalization or other benefit
plans which do not discriminate in scope, terms or operation in favor
of officers or directors and which are available generally to all
salaried employees.
(2) Dr. Joseph has also been issued options for 160,000 shares of Common
Stock. See "Item 10. Security Ownership of Management and Certain
Securityholders."
(3) Ms. Nitka has also been issued options for 60,000 shares of Common
Stock. See "Item 10. Security Ownership of Management and Certain
Securityholders."
(4) Mr. Wilson has also been issued options for 60,000 shares of Common
Stock. See "Item 10. Security Ownership of Management and Certain
Securityholders."
(5) As a group, the Company's officers and directors have also been issued
options for 400,000 shares of Common Stock. See "Item 10. Security
Ownership of Management and Certain Securityholders."
STOCK OPTION PLAN. Under the Company's 1998 Stock Option Plan (the
"Option Plan"), all officers and directors of the Company, as well as its
employees and consultants, are eligible to be selected to participate. The
purpose of the Option Plan is to promote the interests of the Company by
providing participants with an inducement to maintain their status with the
Company and to further advance the interests of the Company. Options are granted
in consideration of things such as past and potential future contributions to
the Company. The Option Plan is administered by a Stock Option Committee (the
"Committee"), which consists of at least two directors appointed by the
Company's Board of Directors.
As of June 23, 1999, 300,000 options have been issued under the Option
Plan. The aggregate number of shares of Common Stock to be delivered upon the
exercise of all options granted under the Option Plan cannot exceed 360,000
shares. In the event of any merger, reorganization, recapitalization, stock
dividend, stock split or reverse split or other act or event which effects a
restructure of the Company's Common Stock (but not including the issuance of
additional shares of Common Stock or preferred stock), the total number of
shares covered by the Option Plan, the exercise price, and number of shares
covered by outstanding options granted pursuant to the Option Plan, and the
rights, preferences and privileges incident to such shares will be appropriately
adjusted as to any remaining options. Any shares covered by options granted
pursuant to the Option Plan which expire or are canceled are available for
reissuance under the Option Plan.
The Committee determines the individuals to whom and the times at which
options are granted and the terms of, and number of shares subject to, each
option. The Committee also has the authority to construe and interpret the
Option Plan. There is no maximum or minimum number of shares which may be
subject to options granted to any one individual under the Option Plan. The
exercise price of the stock covered by each option is also determined by the
Committee; provided, however, that (i) as to incentive stock options, such
exercise price will not be less than an amount equal to 100% of the "fair value"
of the stock (as determined pursuant to the Option Plan) on the date the option
is granted (110% for options granted to persons who hold 10% or more of the
Company's Common Stock) and (ii) as to all other options, such exercise price
will not be less than an amount equal to 85% of the fair value of the stock on
the date the option is granted. Upon the exercise of an option granted under the
Option Plan, the exercise price is payable in full at the time of exercise,
either in cash, by check, in stock of the Company valued at fair market value at
the time of each such exercise or, in the Committee's discretion, by delivery of
a promissory note. Subject to the express provisions of the Option Plan, the
terms of each option granted under the Option Plan, including the exercise
price, manner of exercise, vesting and duration of each option, shall be as
specified in the applicable option agreement between the Company and the option
holder.
As a general proposition, if the option holder ceases, for any reason,
to be an employee of the Company, or a director of the Company, as the case may
be, the option holder will have a right thereafter to exercise the option during
a specified period set forth in the option agreement between the Company and the
option holder, which in the event of termination due to death or permanent
disability, will be no more than three years and which, in all other cases, will
be no more than one year.
Options granted under the Option Plan are not assignable or
transferable except by will or the laws of descent and distribution, and are
exercisable during the option holder's lifetime only by the option holder. No
options will be exercisable
- 9 -
<PAGE>
more than ten years after the date of grant (five years for options granted to
persons holding 10% or more of the Company's Common Stock).
Upon the anticipated occurrence of certain specified events, including
a merger, consolidation or other transaction in which the Company ceases to be
an independent corporation, the Committee, in its discretion, may provide that
all options granted under the Option Plan will become exercisable in full for a
specified period prior to such event.
The Board of Directors of the Company or the Committee may amend,
suspend or terminate the Option Plan at any time. Unless terminated sooner, the
Option Plan will terminate on June 15, 2008 and no options may be granted
thereafter. No amendment, suspension or termination of the Option Plan will,
without the consent of the option holder, be made which would alter or impair
any rights or obligations under any option then outstanding. Upon the
dissolution or liquidation of the Company, the Option Plan will terminate, and
any option previously granted thereunder and not yet exercisable in full will
also terminate. In the event, however, that the Company is succeeded by another
corporation, the Option Plan and any remaining options granted thereunder will
be assumed by such successor corporation, subject to such adjustments as may be
necessary due to the capital structure of the successor corporation.
COMPENSATION ARRANGEMENTS. On May 15, 1998, the Company entered into a
three-year employment agreement with Adrian A. Joseph. The employment agreement
automatically renews for succeeding terms of one year, subject to the prior
notification of termination by either the Company or Dr. Joseph. Annual
compensation pursuant to the employment agreement is $180,000 per year, payable
monthly, subject to annual increases at the discretion of the Company's Board of
Directors. Dr. Joseph is also to receive an annual bonus equal to 10% of the
amount of annual Company profits which exceeds $300,000 over the Company's prior
year's profits. Although the employment agreement includes non-disclosure
covenants as to the Company's trade secrets, Dr. Joseph is permitted to pursue
other opportunities while serving as President of the Company, but only with the
consent of the Board of Directors.
The Company has also entered into an employment agreement with Sharon
Nitka. That agreement is terminable by the Company at any time, without cause,
and provides for an annual salary of $36,000 plus reimbursement of reasonable
expenses incurred in the furtherance of the Company's business.
The Company has entered into consulting agreements with William A.
Wilson, Rita M. Lavelle and John R. Longenecker, each of whom is a director of
the Company. Pursuant to those agreements (each of which is terminable by either
party on 30-days notice), the Company pays consulting fees of $2,000 per month
(which increased to $4,000 per month for Ms. Lavelle on March 1, 1999), plus
reimbursement of Company-approved expenses.
Except as noted above, the Company does not compensate its directors
for their services as such, although they have been granted options under the
Company's Option Plan. See "Stock Option Plan" above. It is, however, the policy
of the Company to reimburse directors for reasonable expenses incurred in
attending meetings of the Board of Directors.
ITEM 10. SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS.
The following table sets forth the record ownership of the Company's
Common Stock (the Company's only class of voting stock) as of June 23, 1999 as
to (i) each person or entity who owns more than 10% of any class of the
Company's securities (including those shares subject to outstanding options),
(ii) each person named in the table appearing in "Item 9. Remuneration of
Directors and Officers" and (iii) all officers and directors of the Company as a
group:
<TABLE>
<CAPTION>
NAME AND ADDRESS OF OWNER NUMBER OF SHARES OWNED(1) PERCENT OF CLASS (2)
- ------------------------- ------------------------- --------------------
<S> <C> <C>
Adrian A. and Dianna Joseph 7,844,000 59.9%
1400 Bristol Street N., Suite 240
Newport Beach, California 92660
Sharon Nitka 350,000(3) 2.7%
1400 Bristol Street N., Suite 240
Newport Beach, California 92660
William A. Wilson 750,000(3) 5.7%
10101 Wilshire Boulevard
Los Angeles, California 90024
</TABLE>
- 10 -
<PAGE>
<TABLE>
<S> <C> <C>
All officers and directors 9,844,000 75.1%
as a group (5 persons)
</TABLE>
- ----------------------
(1) To the Company's knowledge, the persons named in the table have sole
voting and investment power with respect to all shares of Common Stock
owned by them, subject to community property laws where applicable.
(2) Based on 13,026,500 shares of Common Stock outstanding, without taking
into account any shares issuable upon the exercise of outstanding
options or warrants.
(3) Does not include shares which can be obtained upon exercise of the
options described in the table below.
Other than the Class "A" Common Stock Purchase Warrants, the Company
has no class of non-voting securities presently outstanding.
The following table sets forth the options, warrants and other rights
to purchase securities of the Company which were held as of June 23, 1999 by (i)
each person or entity who owns more than 10% of any class of the Company's
securities, (ii) each person named in the table appearing in "Item 9.
Remuneration of Directors and Officers" and (iii) all officers and directors of
the Company as a group:
<TABLE>
<CAPTION>
TITLE AND AMOUNT
OF SECURITIES CALLED
FOR BY OPTIONS, EXPIRATION
NAME OF HOLDER WARRANTS OR RIGHTS(1) EXERCISE PRICE DATE
- --------------------------- ------------------------------------- -------------- ----------
<S> <C> <C> <C>
Adrian A. Joseph 100,000 shares of Common Stock $1.00/share Varies(2)
60,000 shares of Common Stock $0.55/share Varies(3)
Sharon Nitka 60,000 shares of Common Stock $0.50/share Varies(3)
William A. Wilson 60,000 shares of Common Stock $0.50/share Varies(3)
All officers and directors 400,000 shares of Common Stock $0.50/share, Varies(2)(3)
as a group (5 persons) $0.55/share and
$$1.00/share
- -------------
</TABLE>
(1) All options in this table are fully vested.
(2) Options are exercisable only during the term of Dr. Joseph's employment
agreement, subject to extension to June 1, 2001 under certain
circumstances.
(3) Options are exercisable until July 31, 2003 as to Dr. Joseph, and until
July 31, 2008 as to the other optionees, subject in each case to
earlier termination in the event of death, disability and certain other
events.
ITEM 11. INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS.
The following is a description of those transactions by the Company
since its inception or which are presently proposed in which (i) any Company
director, officer, promoter or greater than 10% shareholder (or a relative or
spouse thereof, or any relative of such spouse) has or is to have a direct or
indirect interest and (ii) the amount involved exceeds $50,000.
On June 12, 1998, the Company issued to Adrian A. Joseph (the Company's
President and majority shareholder) 10,000,000 shares of Common Stock in return
for his assignment of the Nurescell Technology which he developed. At that time,
the Company also paid Dr. Joseph approximately $34,000 for certain materials and
supplies owned by him in connection with the development of that technology.
The Company has also entered into employment agreements with Dr. Joseph
and Sharon Nitka (the Company's Chief Financial Officer and Secretary and a
director), as described above in "Item 9. Remuneration of Directors and
Officers," and has granted stock options to Dr. Joseph and Ms. Nitka, as
described in "Item 10. Security Ownership of Management and Certain
Securityholders."
The Company has entered into consulting agreements with Rita M.
Lavelle, William A. Wilson and John R. Longenecker (each of whom is a director),
as described above in "Item 9. Remuneration of Directors and Officers." The
- 11 -
<PAGE>
Company has also granted stock options to each of those persons, as described in
"Item 10. Security Ownership of Management and Certain Securityholders."
PART II
ITEM 1. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT'S COMMON EQUITY AND
OTHER SHAREHOLDER MATTERS.
The Company's Common Stock is quoted on the OTC Bulletin Board under
the symbol "NUSL" and has been so quoted since June 22, 1999. Prior to that
date, there was no public trading market for the Company's equity securities. In
addition, the Company's Class "A" Common Stock Purchase Warrants (the "Class A
Warrants") are quoted on the OTC Bulletin Board under the symbol "NUSLW."
The following table sets forth the quarterly high and low bids for the
Company's Common Stock as reported by the OTC Bulletin Board since the beginning
of public trading:
<TABLE>
<CAPTION>
COMMON STOCK
----------------------
FISCAL YEAR 2000 HIGH* LOW*
<S> <C> <C>
First quarter (starting June 22, 1999) . . . . . . . . . $5.50 $4.00
</TABLE>
- ---------
* These quotations reflect inter-dealer prices, without retail
mark-up, mark-down or commission, and may not represent actual
transactions.
The Company has not paid any cash dividends on its Common Stock since
its incorporation and anticipates that, for the foreseeable future, earnings, if
any, will continue to be retained for use in its business. As of March 31, 1999,
the number of record holders of the Company's Common Stock was 220.
ITEM 2. LEGAL PROCEEDINGS.
The Company is not currently a party to any legal proceedings and, to
the knowledge of management, there is no litigation threatened by or against the
Company.
ITEM 3. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS.
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
There were no matters submitted to a vote of security holders during
the quarter ended March 31, 1999.
ITEM 5. COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT.
During the fiscal year ended March 31, 1999, the Company was not
required to file forms in compliance with Section 16(a) of the Securities
Exchange Act of 1934 (the "Exchange Act"). Filing of those forms was required
beginning on April 12, 1999, the date the Company's Registration Statement on
Form 10-SB became effective.
ITEM 6. REPORTS ON FORM 8-K.
The Company did not file any reports on Form 8-K during the quarter
ended March 31, 1999.
- 12 -
<PAGE>
PART F/S
INDEX TO FINANCIAL STATEMENTS.
<TABLE>
<CAPTION>
PAGE
<S> <C>
Report of Independent Accountants F-2
Balance Sheet as of March 31, 1999 F-3
Statements of Operations for the period from May 12, 1998
(date of inception) to March 31, 1999 F-4
Statement of Changes in Stockholders' Equity for the period
from May 12, 1998 (date of inception) to March 31, 1999 F-5
Statement of Cash Flows for the period from May 12, 1998
(date of inception) to March 31, 1999 F-6
Notes to Financial Statements F-7
</TABLE>
F-1
<PAGE>
RONALD L. JAMIESON, CPA
Certified Public Accountants
4281 Katella Ave, Suite 117, Los Alamitos, CA 90720
(714)821-9690 * (562)598-8549 * Fax (714)821-9286
June 15, 1999
To the Board of Directors
Nurescell Inc.
Irvine, CA 92614
I have audited the accompanying balance sheets of Nurescell Inc. (a development
stage company) as of March 31, 1999, and the related statements of operations,
stockholders' equity (deficiency) and cash flows for the period from May 12,
1998 (inception) to March 31, 1999. These financial statements are the
responsibility of the Company's management. My responsibility is to express an
opinion on these financial statements based on my audit.
I conducted my audit in accordance with generally accepted auditing standards.
Those standards require that I plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentaion. I
believe that my audit provides a reasonable basis for my opinion.
In my opinion, the financial statements referred to above present fairly, in all
material respects, the balance sheet of Nurescell as of March 31, 1999, and the
results of its operations and its cash flows for the period from May 12, 1998
(inception) to March 31, 1999, in conformity with generally accepted accounting
principles.
The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company is a development stage
enterprise engaged in developing certain radiation shielding technology. As
discussed in Note 1 to the financial statements, the Company's accumulated
losses from operations and negative operating cash flows; its necessity to
obtain additional financing to fund operations until the necessary regulatory
approvals are obtained, if ever; and its ability to ultimately attain successful
operations raise substantial doubt about its ability to continue as a going
concern. Management's plans concerning these matters are described in Note 1.
The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.
/s/ Ronald L. Jamieson, CPA
---------------------------
Ronald L. Jamieson, CPA
F-2
<PAGE>
NURESCELL INC.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEET
March 31, 1999
<TABLE>
<S> <C> <C>
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 125,421
Stock subscriptions receivable 25,000
Advances to employees 12,075
Note receivable officer 54,673
Other receivables 3,761
----------
Total Current Assets $ 220,930
PROPERTY PLANT AND EQUIPMENT at cost, less accumulated
depreciation of $5,881 43,100
OTHER ASSETS
Deposits 3,000
Intangibles 18,609
----------
Total Other Assets 21,609
----------
TOTAL ASSETS 285,639
----------
----------
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)
CURRENT LIABILITIES
Accounts payable $ 34,836
Accrued Salaries 3,000
Payroll Taxes Payable 6,839
----------
$ 44,665
STOCKHOLDERS' EQUITY (DEFICIENCY)
Common stock; $.0001 par, 50,000,000 shares
authorized, 13,077,000 shares issued and
outstanding 1,308
Common stock subscribed; $.0001 par,
5,000 shares -
Additional paid in capital 884,192
Deficit accumulated during the development stage (644,526)
----------
240,974
----------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) $ 285,639
----------
----------
</TABLE>
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS
F-3
<PAGE>
NURESCELL INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF OPERATIONS
FOR THE PERIOD FROM MAY 12, 1998 (DATE OF INCEPTION) TO
MARCH 31, 1999
<TABLE>
<S> <C>
OPERATING EXPENSES:
Research and development $ 2,000
General and administrative 640,041
Depreciation 5,881
-----------
Total expenses 647,922
-----------
Loss from operations (647,922)
OTHER INCOME:
Interest Income 3,396
-----------
NET LOSS $ (644,526)
-----------
-----------
NET LOSS PER SHARE
Basic and fully diluted $ (0.05)
-----------
-----------
Weighted average common shares outstanding $11,886,066
-----------
-----------
</TABLE>
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS
F-4
<PAGE>
NURESCELL INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)
For the Period from May 12, 1998 (Date of Inception) to
March 31, 1999
<TABLE>
<CAPTION>
ADDITIONAL COMMON
COMMON STOCK PAID-IN STOCK ACCUMULATED
SHARES AMOUNT CAPITAL SUBSCRIBED DEFICIT
---------- ------ ---------- ---------- -----------
<S> <C> <C> <C> <C> <C>
Issuance of common stock:
Cash - Founding Shareholders 2,500,000 $ 250 $ 2,250
Technology agreement 10,000,000 1,000 9,000
Cash - $1.00 per share 498,000 50 497,950
Cash - $5.00 per share, net of
issuance cost 79,000 8 349,992
Common stock subscriptions 25,000
NET LOSS $ (644,526)
---------- ------ ---------- ---------- -----------
BALANCE, MARCH 31, 1999 13,077,000 $1,308 $ 884,192 $ - $ (644,526)
---------- ------ ---------- ---------- -----------
---------- ------ ---------- ---------- -----------
</TABLE>
F-5
<PAGE>
NURESCELL INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENT OF CASH FLOWS
For the Period from May 12, 1998 (Date of Inception) to
March 31, 1999
<TABLE>
<S> <C>
CASH FLOWS IN OPERATING ACTIVITIES:
Net loss $ (644,526)
Adjustments to reconcile net loss to net cash used in
Operating activities:
Depreciation 5,881
Changes in assets and liabilities:
Advances to employees (12,075)
Deposits (3,000)
Other receivable (3,761)
Accounts payable 34,826
Accrued salaries 3,000
Accrued payroll taxes 6,839
------------
Net Cash Flows Used by Operating Activities (612,816)
------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant & equipment (48,981)
Acquistion of intangibles (18,609)
Issuance of note receivable (54,673)
------------
Net Cash Flows Used by Investing Activities (122,263)
------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock 860,500
------------
Net Cash Flows Provided by Financing Activities 860,500
------------
NET INCREASE IN CASH
CASH AT BEGINNING OF PERIOD
------------
CASH AT END OF PERIOD $ 125,421
------------
------------
SUPPLEMENTAL DISCLOSURES:
Noncash Investing and Financing Transactions:
Fair market value of intangibles acquired $ 10,000
</TABLE>
SEE ACCOMPANYING NOTES TO FINANCIAL STATEMENTS
F-6
<PAGE>
NURESCELL INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
March 31, 1999
1. GENERAL
NATURE OF BUSINESS
The Company was incorporated on May 12, 1998, pursuant to the laws of the
State of Nevada under the name Nurescell Inc. The Company is currently
engaged in the research, development and testing of its proprietary
radiation shielding technology.
GOING-CONCERN
The accompanying financial statements have been prepared based on the
assumption that the Company will continue as a going-concern. This
assumption anticipates that the Company will be able to realize assets and
satisfy obligations in the normal course of business. The Company has
accumulated net losses of $644,526 and negative cash flows from operating
activities of $612,816 from inception to March 31, 1999. The Company has
not completed testing and development nor obtained patents on its principal
technology. The technology must undergo further development and testing
before the Company will be able to generate any significant commercial
revenues. The Company anticipates that research, development and testing
will require significant additional financing. Management intends to seek
the additional financing through future private placement offerings, joint
ventures, and research grants. The Company's capacity to operate as a
going-concern is dependent on its ability to obtain adequate financing to
fund its operations until the Company is able to complete the necessary
research, development and testing necessary to generate commercial revenues
sufficient to fund ongoing operations. These factors, among others, raise
substantial doubt about the Company's ability to continue as a
going-concern. The financial statements do not include any adjustments that
might result from the outcome of this uncertainty.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
FISCAL YEAR END
In March, 1999, the Board of Directors approved management's plan to change
the Company's fiscal year from a calendar year to a fiscal year ending
March 31, 1999.
RECLASSIFICATIONS
Certain prior quarter balances have been reclassified to conform with the
current year-end presentation.
In 1998, the American Institute of Certified Public Accountants (AICPA)
amended the AICPA SOP and Audit and Accounting Guides addressing the
reporting of costs of start-up activities. Effective for fiscal years
beginning after December 15, 1998, SOP No. 98 require costs of start-up
activities and organizational costs to be expensed as incurred. Because
early application is encouraged in prior periods, the Company has restated
the financial statements to conform. To date, approximately $85,408 of
startup costs and organizational expense have been expensed.
The Company will adopt these required changes on all subsequent statements.
F-7
<PAGE>
NURESCELL INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
March 31, 1999
USE OF ESTIMATES
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates.
RESEARCH AND DEVELOPMENT COSTS
Research and development costs are expensed as incurred. Such costs were
approximately $2,000 in the fiscal year ended March 31, 1999.
BASIS OF PRESENTATION
Since the Company has no revenues and has not yet commenced its principal
operations, it is considered a "development stage enterprise," as defined by
Statement of Financial Accounting Standards No. 7, Accounting and Reporting by
Development Stage Enterprises.
CASH AND CASH EQUIVALENTS
Cash and cash equivalents for the statement of cash flows include cash and cash
on deposit. The Company maintains its cash balance in one financial institution.
During the fiscal year, the Company's cash balance periodically exceeded the
financial institution's insured Federal Deposit Insurance Corporation limit of
$100,000.
PROPERTY AND EQUIPMENT
Property and equipment is stated at cost. Expenditures for maintenance and
repairs are charged to operations as incurred while renewals and improvements
are capitalized. Depreciation of furniture, fixtures, and equipment is computed
using the straight-line method. Estimated useful lives for reporting purposes
are as follows:
<TABLE>
<S> <C>
Furniture, fixtures, and equipment 5 Years
</TABLE>
OTHER ASSETS
Other assets consist of deposits and intangibles. Intangibles include patent
application (and associated legal costs) and certain technology acquisition
costs. Upon commencement of operations, all costs associated with obtaining
patents and technology acquisition costs will be amortized on a straight-line
basis over a 17-year period. The Company will evaluate the recoverability of
intangibles on an annual basis by comparing the estimated net realizable value
of the intangibles to their carrying value. Organization costs and start up
costs have been expensed in accordance with AICPA pronouncement (SOP-98.5).
F-8
<PAGE>
NURESCELL INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
March 31, 1999
LOSS PER SHARE
In 1997 the Financial Accounting Standards Board issued Statement No. 128,
Earnings per Share. Statement 128 replaced the calculation of primary and
fully diluted loss per share with basic and diluted loss per share. Unlike
primary loss per share, basic loss per share excludes any dilutive effects
of options, warrants and convertible securities. Diluted loss per share is
very similar to the previously reported fully diluted loss per share. The
basic and diluted loss per share is computed based on the weighted average
number of common shares outstanding. Common equivalent shares are not
included in the per share calculations where the effect of their inclusion
would be antidilutive. Options to purchase shares of common stock are not
included in the computation of diluted loss per share since the effect
would be antidilutive.
INCOME TAXES
The Company accounts for its income taxes in accordance with the
standards specified in SFAS No. 109, Accounting for Income Taxes.
3. INTANGIBLE ASSETS
On June 12, 1998, the Company entered into a Sale of Technology Agreement
("Agreement") with Dr. Adrian Joseph (now an Officer of the Company)
whereby the Company acquired all rights, title and interest in a new
generation of flexible containment material ("Nuresfoam") for fissionable
nuclear material ("Technology"). The Technology is based, in part, on prior
patented technology, however the Technology itself has not yet be patented
nor trademarked. An U.S. patent has been applied for with the U.S.
Patent Office, U.S. Patent Application 09/187,641.
As consideration for the sale of the Technology, Dr. Joseph received
10,000,000 shares or 80% of the Company's then outstanding common stock.
The transfer of the Technology was intended to be a tax-free exchange in
accordance with Internal Revenue Code Section 351. The Agreement stated
that the Company valued the Technology at $5,000,000; however, an
independent valuation of the technology was not obtained. Consequently, the
Technology has been recorded at a nominal value of $10,000 based on the
fair value ($.0001 per share) of the common stock issued in exchange for
the Technology on the date of transfer.
4. COMMITMENTS AND CONTINGENCIES
OPERATING LEASES
The Company leases office space under an operating sublease that requires
minimum monthly payments of $3,719. Rent expense for the period ended March
31, 1999 was $45,619.
Effective June 1, 1999, the Company has moved to a new location and has
entered into a new three year lease that requires minimum monthly payments
of $3,422.
F-9
<PAGE>
NURESCELL INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
March 31, 1999
The estimated future minimum lease payments under all operating leases for
the years ending March 31, are as follows:
<TABLE>
<CAPTION>
Period Ending
---------------------------------
March 31
--------
<S> <C>
2000 $ 41,658
2001 41,064
2002 41,064
----------
Total $ 123,786
----------
----------
</TABLE>
5. INCOME TAXES
For federal income tax purposes, approximately $644,526 of net operating
loss carryforwards exists to offset future taxable income. These
carryforwards expire in 2014. No tax benefit has been reported in the
accompanying financial statements, however, because management believes
that there is at least a 50% chance that the carryforwards will expire
unused. Accordingly, the $279,080 tax benefit of the cumulative
carryforwards has been offset by a valuation allowance of the same amount.
6. COMMON STOCK
The Company has 50,000,000 shares of $.0001 par value common stock
authorized of which and 13,077,000 shares were issued and outstanding at
March, 31, 1999.
Common stock issued from issuance of $5.00 shares has been reflected net of
offering expenses of approximately of $45,000.
7. STOCK OPTIONS
Effective June 15, 1998, the stockholders approved an Incentive Stock
Option Plan granting to any Director, Officer, Employee or Consultant to
the Company options to purchase Company Common Stock over a ten-year
period, at the fair market value at time of grant. The aggregate number of
common shares of the Company, which may be granted under the plan is
360,000 shares. In addition to options for 300,000 shares which have been
granted under the plan, the Company has also granted options for 100,000
shares to an Officer pursuant to his employment agreement. No options were
exercised as of March 31, 1999.
8. STOCK WARRANTS
Effective September 15, 1998 the stockholders approved a plan to issue
units consisting of one share of Common Stock (the "Common Stock") and one
Class "A" Common Stock Purchase Warrant (the "Class A Warrants") of the
Company.
The Class "A" Warrants are exercisable into one (1) share of Common Stock
and one (1) Class "B" Common Stock Purchase Warrant (the "Class "B"
Warrant") commencing the day immediately after the first anniversary of the
closing of the offering (the "A" Exercise Date") and have an exercise price
of $4.00. The Class "A" Warrants expire on the first anniversary of the "A"
Exercise Date (the "A" Expiration Date"). The Class "B" Warrants are
exercisable into one (1) share of Common Stock commencing immediately upon
their issuance (the "B" Exercise Date") and have an exercise price of $3.00
per share of Company Common Stock. The Class "B" Warrants expire on the
first anniversary of the "B" Exercise Date.
F-10
<PAGE>
NURESCELL INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
March 31, 1999
Prior to permitting the exercise of either the Class "A" or Class "B"
Warrants offered hereby, the Company will be required to either register
the underlying Common Stock or seek an exemption from registration under
both federal and state law. The Common Stock and the Class "A" warrant are
immediately detachable.
9. RELATED PARTIES
The Company has made unsecured loans of $54,673, including interest, to one
of its officers. These 10% interest-bearing loans are evidenced by notes
and are all due within twelve months.
The Company has also entered into consulting contracts with certain
Directors as a means of inducing the Directors to devote additional time
and effort to the Company over and above the time normally expected of a
Director. These contracts provide for payments of $2,000 to $4,000 per
month to each Director under contract, have no stated termination date but
are cancelable by either party on 30 days written notice. Amounts paid by
the Company under these contracts were $74,599, respectively at March 31,
1999.
The Company purchased various chemicals, lab equipment, research material
and start-up expenses from a related party. The purchases of lab equipment,
research materials and start-up expenses amounted to $20,000 during the
period ended March 31, 1999. The purchase of chemicals for the period ended
March 31, 1999 amounted to $14,000.
10. SUBSEQUENT EVENTS
SIGNIFICANT CONTRACTS AND AGREEMENTS
On March 1, 1999, the Company entered into a letter of understanding
("LOU") with Performance Improvement International ("PII"). Under the LOU,
PII will provide certain marketing, product development, specification
review and other services to the Company related to nuclear power plants.
PII is headed by Dr. Chang Chiu, a former Dean of Physics at the
Massachusetts Institute of Technology and the former General Manager of the
San Onofre Nuclear Power Station. The LOU provides for PII to receive a
percentage of all nuclear power plant net revenues generated as a direct
result of PII's services.
The Company is currently in discussions with a Southern California based
entity to raise approximately $5,000,000 on a "best efforts" basis through
a private-offering of equity securities. Although the Company has received
a letter of commitment from the entity outlining the general terms of the
fund raising, no formal agreements have been signed to date. These
discussions are preliminary in nature and there is no guarantee that the
Company will be able to consummate any offering whereby the Company will
receive all or any portion of the $5,000,000 at any time during the near or
distant future.
The Company is currently involved in negotiations with Battelle Memorial
Institute, Pacific Northwest Division (PNNL) in order to establish a
working relationship for the testing and qualification of the Technology.
In this context, the Company is discussing the benefit of forming a joint
venture, known as "CRADA" versus a private venture with PNNL.
F-11
<PAGE>
NURESCELL INC.
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
March 31, 1999
In parallel with the work by PNNL, the Company has entered into an
agreement with the University of Missouri for product testing with respect
to high levels of alpha, beta and gamma radiation. This work will be
accomplished in a twelve month period at an approximate cost of $151,064.
After the performance of the Technology has been satisfactorily evaluated
by PNNL, the Company will seek to incorporate Technology based products
into field studies of specialized applications and into bench scale and
field trials of specialized private enterprise equipment. Simultaneous with
that phase, the Company will use its best efforts to seek out and form
various strategic alliances for the use of its products in nuclear material
handling equipment and applications.
The Company has agreed to repurchase 2,000 shares at the original cost of
$10,000 from an investor.
The Company, in return for introducing investors to the Company, has
offered to select individuals options to purchase one share of the Company
common stock at one dollar ($1.00) for every share of the Company common
stock sold to any investor introduced to the Company by such individual.
This option is to be excercised only twelve (12) months after the
completion of the transaction mentioned above, (i.e. "exercising day") and
the option will be good for twenty-four (24) months after the exercising
day.
SECURITIES OFFERINGS
The Company had previously completed a securities offering under Rule 504
of Regulation D ("Rule 504") pursuant to an Offering Memorandum dated June
22, 1998. In addition, the Company has completed an offering of additional
securities (consisting of Common Stock and Class A Warrants) under Rule 504
pursuant to an Offering Memorandum dated September 18, 1998.
The Company has filed a Form 10-SB registration statement with the
Securities and Exchange Commission, which filing has now become effective.
The Company's Common Stock is quoted on the OTC Bulletin Board under the
symbol "NUSL", and has been so quoted since June 10, 1999. Prior to that
date, there was no public trading market for the Company's equity
securities. In addition, the Company's Class "A" Common Stock Purchase
Warrants (the "Class A Warrants") are quoted on the OTC Bulletin Board
under the symbol "NUSLW".
F-12
<PAGE>
NURESCELL INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
MARCH 31, 1999
11. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
Selected unaudited quarterly financial data for fiscal 1999 is summarized
as follows:
<TABLE>
<CAPTION>
Fiscal 1999 Quarters Ended
--------------------------------
5-12-98
(Date of Inception)
to
6-30-98 9-30-98 12-31-98 3-31-99
------- ------- -------- -------
(In thousands, except per share data)
<S> <C> <C> <C> <C>
Operating expenses $ (78) $ (169) $ (228) $ (173)
Other income 2 1
Net loss (78) (169) (226) (172)
Net loss per share (.01) (.01) (.02) (.01)
</TABLE>
Prior quarter results have been restated pursuant to SOP 98. This change had
the effect of increasing prior quarter operating expenses.
Quarter ended June 30, 1998 reflects activity from May 12, 1998 (date of
inception) to June 30, 1998.
F-13
<PAGE>
PART III
INDEX TO EXHIBITS AND DESCRIPTION OF EXHIBITS.
The following exhibits are included as part of this Report:
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
----------- -----------
<S> <C>
2.1 Articles of Incorporation, as amended(1)
2.2 Bylaws(1)
3.1 Form of Class "A" Common Stock
Purchase Warrant Certificate(1)
3.2 Form of Class "B" Common Stock
Purchase Warrant Certificate(1)
6.1 Employment Agreement between the
Company and Adrian A. Joseph, Ph.D.
dated May 15, 1998(1)
6.2 Sale of Technology between the Company
and Adrian A. Joseph dated June 12, 1998(1)
6.3 Employment Agreement between the
Company and Sharon Nitka dated
June 1, 1998(1)
6.4 Consulting Agreement between the
Company and John Longenecker
dated June 26, 1998(1)
6.5 Consulting Agreement between the
Company and William A. Wilson dated
June 10, 1998(1)
6.6 Consulting Agreement between the Company
and Rita Lavelle dated June 1, 1998(1)
6.7 Form of Stock Option Agreement between the
Company and its officers and directors(1)
6.8 1998 Stock Option Plan(1)
6.9 Form of Indemnification Agreement between the
Company and its officers and directors(1)
6.10 Letter of Understanding for Proposed Agreement
Between the Company and Performance Improvement
International dated March 1, 1999(2)
6.11 Research Plan submitted by the University of
Missouri to the Company(2)
12.1 Consent of Auditor
12.2 Power of Attorney
</TABLE>
III-1
<PAGE>
<TABLE>
<S> <C>
27 Financial Data Schedule
</TABLE>
- ------------
(1) Incorporated by reference from the Company's Registration
Statement on Form 10-SB (File No. 0-25377). Exhibit numbers
from that Registration Statement have been retained.
(2) Incorporated by reference from Amendment No. 1 to the
Company's Registration Statement on Form 10SB (File No.
0-25377). Exhibit numbers from that Registration Statement
have been retained.
III-2
<PAGE>
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the
Registrant has caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Newport Beach, State of California, on
the 28th day of June, 1999.
NURESCELL INC.
By: /s/ Adrian A. Joseph
----------------------------
Adrian A. Joseph, President
Principal Executive Officer
By:/s/ Sharon Nitka
-----------------------------
Sharon Nitka, Chief Financial Officer
Principal Financial and Accounting Officer
In accordance with the Exchange Act, this report has been signed below
by the following persons on behalf of the Registrant and in the capacities and
on the dates indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
- --------- ----- ----
<S> <C> <C>
/s/ William A. Wilson Chairman of the Board June 28, 1999
- ---------------------
*William A. Wilson
/s/ Rita M. Lavelle Director and Vice President - Marketing June 28, 1999
- -----------------------
*Rita M. Lavelle
/s/ John R. Longenecker Director and Vice President - Operations June 28, 1999
- -----------------------
*John R. Longenecker
/s/ Sharon Nitka Director, Chief Financial Officer and Secretary June 28, 1999
- ------------------------
*Sharon Nitka
*By:/s/ Adrian A. Joseph
--------------------
Adrian A. Joseph,
Attorney-in-Fact
</TABLE>
III-3
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
----------- -----------
<S> <C>
2.1 Articles of Incorporation, as amended(1)
2.2 Bylaws(1)
3.1 Form of Class "A" Common Stock
Purchase Warrant Certificate(1)
3.2 Form of Class "B" Common Stock
Purchase Warrant Certificate(1)
6.1 Employment Agreement between the
Company and Adrian A. Joseph, Ph.D.
dated May 15, 1998(1)
6.2 Sale of Technology between the Company
and Adrian A. Joseph dated June 12, 1998(1)
6.3 Employment Agreement between the
Company and Sharon Nitka dated
June 1, 1998(1)
6.4 Consulting Agreement between the
Company and John Longenecker
dated June 26, 1998(1)
6.5 Consulting Agreement between the
Company and William A. Wilson dated
June 10, 1998(1)
6.6 Consulting Agreement between the Company
and Rita Lavelle dated June 1, 1998(1)
6.7 Form of Stock Option Agreement between the
Company and its officers and directors(1)
6.8 1998 Stock Option Plan(1)
6.9 Form of Indemnification Agreement between the
Company and its officers and directors(1)
6.10 Letter of Understanding for Proposed Agreement
Between the Company and Performance Improvement
International dated March 1, 1999(2)
6.11 Research Plan submitted by the University of
Missouri to the Company(2)
12.1 Consent of Auditor
12.2 Power of Attorney
27 Financial Data Schedule
</TABLE>
- ------------
<PAGE>
(1) Incorporated by reference from the Company's Registration
Statement on Form 10-SB (File No. 0-25377). Exhibit numbers
from that Registration Statement have been retained.
(2) Incorporated by reference from Amendment No. 1 to the
Company's Registration Statement on Form 10SB (File No.
0-25377). Exhibit numbers from that Registration Statement
have been retained.
<PAGE>
Exhibit 12.1
CONSENT OF INDEPENDENT ACCOUNTANTS
I consent to inclusion in this Report on Form 10-KSB of my report dated
June 15, 1999 on my audit of the financial statements of Nurescell Inc.
RONALD L. JAMIESON, CPA
Los Alamitos, California
June 24, 1999
<PAGE>
Exhibit 12.2
POWER OF ATTORNEY
KNOW ALL PERSON BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints ADRIAN A. JOSEPH as his or her true and
lawful attorney-in-fact and agent, with full power of substitution and
resubstitution, for him or her and in his or her name, place and stead, in any
and all capacities, to sign NURESCELL INC.'s Form 10-KSB report for the year
ended March 31, 1999 and any and all amendments thereto, and to file the same,
with all exhibits thereto, and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorney-in-fact and
agent full power and authority to do and perform each and every act and thing
requisite and necessary to be done in connection therewith, as fully to all
intents and purposes as he or she might or could do in person and hereby
ratifying and confirming all that said attorney-in-fact and agent, or his
substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
- --------- ----- ----
<S> <C> <C>
/s/ William A. Wilson Chairman of the Board June 12, 1999
- ---------------------
William A. Wilson
/s/ Rita M. Lavelle Director and Vice President - Marketing June 16, 1999
- -------------------
Rita M. Lavelle
/s/ John R. Longenecker Director and Vice President - Operations June 16, 1999
- -----------------------
John R. Longenecker
/s/ Sharon Nitka Director, Chief Financial Officer and Secretary June 16, 1999
- ----------------
Sharon Nitka
</TABLE>
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF NURESCELL INC. (A DEVELOPMENT STAGE COMPANY) FOR THE
PERIOD FROM MAY 12, 1998 (DATE OF INCEPTION) TO MARCH 31, 1999 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> OTHER
<FISCAL-YEAR-END> MAR-31-1999
<PERIOD-START> MAY-12-1998
<PERIOD-END> MAR-31-1999
<CASH> 125,421
<SECURITIES> 0
<RECEIVABLES> 87,285
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 220,930
<PP&E> 48,981
<DEPRECIATION> (5,881)
<TOTAL-ASSETS> 285,639
<CURRENT-LIABILITIES> 44,665
<BONDS> 0
0
0
<COMMON> 1,308
<OTHER-SE> 859,192
<TOTAL-LIABILITY-AND-EQUITY> 285,639
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 647,922
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 0
<INCOME-TAX> 0
<INCOME-CONTINUING> (644,526)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (644,526)
<EPS-BASIC> 0
<EPS-DILUTED> 0
</TABLE>
